Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00 at TD Cowen

Gilead Sciences (NASDAQ:GILD) had its target price increased by TD Cowen from $125.00 to $145.00 in a report published on Thursday morning,MarketScreener reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on GILD. Truist Financial lifted their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday. The Goldman Sachs Group increased their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. Citigroup lifted their price objective on Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research report on Tuesday. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Finally, Argus boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $136.36.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded up $0.74 during midday trading on Thursday, hitting $140.29. The company had a trading volume of 363,299 shares, compared to its average volume of 7,282,596. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The business’s 50-day simple moving average is $125.05 and its 200-day simple moving average is $119.38. The stock has a market cap of $174.05 billion, a price-to-earnings ratio of 21.77, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $141.71.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. Gilead Sciences’s revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the business posted $2.02 EPS. On average, research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the chief financial officer owned 150,503 shares in the company, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 257,397 shares of company stock worth $33,385,512. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

Large investors have recently added to or reduced their stakes in the business. Personal CFO Solutions LLC raised its holdings in shares of Gilead Sciences by 1.7% during the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after acquiring an additional 76 shares in the last quarter. Moss Adams Wealth Advisors LLC increased its holdings in Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after buying an additional 76 shares during the period. SOA Wealth Advisors LLC. boosted its holdings in Gilead Sciences by 8.7% during the fourth quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 81 shares in the last quarter. Trivium Point Advisory LLC grew its stake in shares of Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares during the period. Finally, Greatmark Investment Partners Inc. lifted its position in shares of Gilead Sciences by 0.3% during the 4th quarter. Greatmark Investment Partners Inc. now owns 29,200 shares of the biopharmaceutical company’s stock worth $3,584,000 after buying an additional 83 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst price-target upgrades — Wolfe Research raised its PT to $155 and kept an outperform rating, and several other firms (Citigroup, Truist, BMO, UBS) also issued higher targets or bullish notes, supporting upside expectations and drawing buying interest. Wolfe Research PT Raise
• Positive Sentiment: Regulatory/clinical momentum for Trodelvy — the drug was added to NCCN guidelines and coverage of a Tropdelvy win in triple?negative breast cancer highlights Gilead’s growing oncology franchise, which is a longer-term revenue catalyst. Trodelvy NCCN Trodelvy TNBC Win
• Positive Sentiment: Institutional and analyst attention — coverage pieces and forecasts from Citi/Truist/BMO point to strong price appreciation expectations, which can attract momentum and ETF/active flows. Citigroup Forecast
• Positive Sentiment: ETF and index presence — commentary noting Gilead’s weighting in Nasdaq/healthcare ETFs can support passive inflows if sector flows continue. ETF Presence
• Neutral Sentiment: Zacks and BarChart note increased investor attention and broad analyst optimism — useful for volume but not an immediate directional catalyst on its own. Zacks Attention Note
• Neutral Sentiment: Short-interest report shows inconsistent/erroneous data (0 shares / NaN change), so there’s no clear short-squeeze signal from the published figures.
• Negative Sentiment: Insider selling — CEO Daniel O’Day sold 10,000 shares at about $139.89 (~$1.4M) on Jan. 28 and has made several recent sales. While not large relative to his holdings, insider sales are often viewed negatively by some investors. SEC Form 4

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.